Latest Breaking News On - Julien mazieres - Page 1 : comparemela.com

 E-Mail (Singapore January 31, 2021 2:40 p.m. SPT 1:40 a.m. EST) Patient-reported outcomes from the phase III CROWN study showed that time to treatment deterioration (TTD) in pain in chest, dyspnea, and cough was comparable between those who received lorlatinib and patients who took crizotinib. The research was presented today at the International Association for the Study of Lung Cancer s 2020 World Conference on Lung Cancer Singapore. Lorlatinib, a third-generation ALK inhibitor, significantly improved progression-free survival compared to crizotinib in patients with previously untreated advanced ALK-positive NSCLC. Dr. Julien Mazieres, Toulouse University Hospital, in Toulouse, France presented the detailed results of patient reported outcomes (PROs) from his same study.

Julien mazieresToulouse university hospitalInternational associationLung cancerThoracic oncologyMedicine healthClinical trialsடவுலஸ் பல்கலைக்கழகம் மருத்துவமனைசர்வதேச சங்கம்நுரையீரல் புற்றுநோய்தொராசி புற்றுநோயியல்மருந்து ஆரோக்கியம்மருத்துவ சோதனைகள்